查找临床试验
已按「多发性硬化」检索，对应国际通用词 multiple sclerosis
共找到 12 项正在招募的试验（在中国／港澳台设有中心）
数据更新于 10:03，每 5 分钟自动同步Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
United States、Australia、Italy、Mexico、Poland 等 11 国
年龄 10 Years – 17 Years
Bristol-Myers Squibb
Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis
Taiwan
年龄 20 Years – 65 Years
Ever Supreme Bio Technology Co., Ltd.
Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
Taiwan
年龄 20 Years – 100 Years
Novartis Pharmaceuticals
Effectiveness of Personalized Alternating Current Stimulation for Treating Cognitive Impairment in CNS Demyelination Patients
China
年龄 18 Years – 65 Years
Xuanwu Hospital, Beijing
Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
China
年龄 3 Years – 不限
The Children's Hospital of Zhejiang University School of Medicine
Clinical Study of Regulatory T Cells (Tregs) in the Treatment of Neurodegenerative Diseases
China
年龄 18 Years – 70 Years
Novabio Therapeutics
Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels
China
年龄 18 Years – 不限
Third Affiliated Hospital, Sun Yat-Sen University
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
United States、Belgium、China、Italy、Japan
年龄 18 Years – 60 Years
Sanofi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
United States、Argentina、Australia、Austria、Belgium 等 12 国
年龄 18 Years – 65 Years
Novartis Pharmaceuticals
China National Registry of Neuro-Inflammatory Diseases
China
年龄 不限 – 不限
Beijing Tiantan Hospital
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis
China
年龄 18 Years – 75 Years
Xijing Hospital
Sun Yat-Sen Cohort of CNS Idiopathic Inflammatory Demyelinating Diseases
China
年龄 18 Years – 65 Years
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University